Filtered By:
Specialty: Neurology
Drug: Gilenya
This page shows you your search results in order of date.
Order by Relevance | Date
Total 19 results found since Jan 2013.
The emerging role of FTY720 as a sphingosine 1 ‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
Three important mechanisms for neuroprotective effects of FTY720 have been described. Functional antagonistic, functional agonistic and receptor-independent mechanisms. Here, we review these mechanisms in more details and describe animal model and in clinical trial studies AbstractFinding novel and effective drugs for the treatment of ischemic stroke is warranted because there is not a definitive treatment for this prevalent disease. Due to the relevance between the sphingosine 1-phosphate (S1P) receptor and several neurological diseases including ischemic stroke, it seems that fingolimod (FTY720), as an agonist of S1P rec...
Source: Brain and Behavior - May 10, 2021 Category: Neurology Authors: Maryam Naseh,
Jafar Vatanparast,
Ali Rafati,
Mahnaz Bayat,
Masoud Haghani Tags: REVIEW Source Type: research
The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia
The role of the immune system in stroke is well-recognised. Fingolimod, an immunomodulatory agent licensed for the management of relapsing-remitting multiple sclerosis, has been shown to provide benefit in rod...
Source: Journal of Neuroinflammation - January 30, 2021 Category: Neurology Authors: Kyle Malone, Andrea C. Diaz Diaz, Jennifer A. Shearer, Anne C. Moore and Christian Waeber Tags: Research Source Type: research
Fingolimod promotes angiogenesis and attenuates ischemic brain damage via modulating microglial polarization.
CONCLUSIONS: Our research indicated that FTY720 treatment promoted angiogenesis via microglial M2 polarization and exerted neuroprotection in PT ischemic stroke.
PMID: 31626784 [PubMed - as supplied by publisher]
Source: Brain Research - October 14, 2019 Category: Neurology Authors: Shang K, He J, Zou J, Qin C, Lin L, Zhou LQ, Yang LL, Wu LJ, Wang W, Zhan KB, Tian DS Tags: Brain Res Source Type: research
Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow
ObjectiveThe present study was undertaken to determine the efficacy of coadministration of fingolimod with alteplase in acute ischemic stroke patients in a delayed time window.MethodsThis was a prospective, randomized, open ‐label, blinded endpoint clinical trial, enrolling patients with internal carotid artery or middle cerebral artery proximal occlusion within 4.5 to 6 hours from symptom onset. Patients were randomly assigned to receive alteplase alone or alteplase with fingolimod. All patients underwent pretreatme nt and 24‐hour noncontrast computed tomography (CT)/perfusion CT/CT angiography. The coprimary endpoint...
Source: Annals of Neurology - November 2, 2018 Category: Neurology Authors: De ‐Cai Tian,
Kaibin Shi,
Zilong Zhu,
Jia Yao,
Xiaoxia Yang,
Lei Su,
Sheng Zhang,
Meixia Zhang,
Rayna J. Gonzales,
Qiang Liu,
DeRen Huang,
Michael F. Waters,
Kevin N. Sheth,
Andrew F. Ducruet,
Ying Fu,
Min Lou,
Fu‐Dong Shi Tags: Research Article Source Type: research
Fingolimod Enhances the Efficacy of Delayed Alteplase Administration in Acute Ischemic Stroke by Promoting Anterograde Reperfusion and Retrograde Collateral Flow
Annals of Neurology,Volume 0, Issue ja, -Not available-.
Source: Annals of Neurology - October 8, 2018 Category: Neurology Authors: De ‐Cai Tian,
Kaibin Shi,
Zilong Zhu,
Jia Yao,
Xiaoxia Yang,
Lei Su,
Sheng Zhang,
Meixia Zhang,
Rayna J. Gonzales,
Qiang Liu,
DeRen Huang,
Michael F. Waters,
Kevin N. Sheth,
Andrew F. Ducruet,
Ying Fu,
Min Lou,
Fu‐Dong Shi Source Type: research
Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway Basic Sciences
Conclusions—Our study suggested that FTY720 might be a potential therapeutic drug targeting brain inflammation by skewing microglia toward M2 polarization after chronic cerebral hypoperfusion.
Source: Stroke - November 27, 2017 Category: Neurology Authors: Chuan Qin, Wen-Hui Fan, Qian Liu, Ke Shang, Madhuvika Murugan, Long-Jun Wu, Wei Wang, Dai-Shi Tian Tags: Ischemic Stroke, Vascular Disease Original Contributions Source Type: research
Fingolimod Confers Neuroprotection through Activation of Rac1 after Experimental Germinal Matrix Hemorrhage in Rat Pups
This article is protected by copyright. All rights reserved.
Source: Journal of Neurochemistry - December 31, 2016 Category: Neurology Authors: William B. Rolland, Paul R. Krafft, Tim Lekic, Damon Klebe, Julia LeGrand, Abby Jones Weldon, Liang Xu, John H. Zhang Tags: Original Article Source Type: research
Selective Sphingosine 1-Phosphate Receptor 1 Agonist Is Protective Against Ischemia/Reperfusion in Mice Brief Report
Conclusions—The selective S1P1 agonist LASW1238 reduces infarct volume after ischemia/reperfusion in mice, but only when lymphopenia is sustained for at least 24 hours. S1P1 and lymphocytes are potential targets for drug treatment in stroke. Defining the best drug dosing regimens to control the extent and duration of lymphopenia is critical to achieve the desired effects.
Source: Stroke - November 27, 2016 Category: Neurology Authors: Vanessa H. Brait, Gema Tarrason, Amadeu Gavalda, Nuria Godessart, Anna M. Planas Tags: Basic Science Research, Inflammation, Ischemia Brief Reports Source Type: research
Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke
Wentao Li, Haoliang Xu, Fernando D. Testai
Source: Frontiers in Neurology - August 25, 2016 Category: Neurology Source Type: research
Fingolimod (FTY720) reduces cortical infarction and neurological deficits during ischemic stroke through potential maintenance of microvascular patency.
Abstract
Fingolimod (FTY720) a functional sphingosine-1-phosphate receptor 1 (S1P1) antagonist reduces infarct volume and improves neurological deficits in different rodent stroke models by modulating inflammatory and immune processes. However, studies on FTY720 regarding its non-immunological efficacy on ischemic cerebral tissue are sparse. Here we investigated whether FTY720 has cytoprotective and restorative properties following ischemic stroke in mice. Male C57Bl/6 mice received FTY720 (1mg/kg) or a vehicle solution intraperitoneally immediately prior to transient middle cerebral artery occlusion (tMCAO; 30 mi...
Source: Current Neurovascular Research - August 22, 2016 Category: Neurology Authors: Fluri F, Schuhmann MK, Krstić M, Kleinschnitz C Tags: Curr Neurovasc Res Source Type: research
Clinical Trials of Immunomodulation in Ischemic Stroke
Abstract
Inflammatory mechanisms are currently considered as a prime target for stroke therapy. There is evidence from animal studies that immune signals and mediators can have both detrimental and beneficial effects in particular stages of the disease process. Moreover, several of these mechanisms are turned on with sufficient delay after ischemia onset to make them amenable to therapeutic intervention. Several clinical proof-of concept trials have investigated the efficacy of different immunomodulatory approaches in patients with stroke. Trials targeting the innate immune system have focused on reduction of micr...
Source: Neurotherapeutics - July 12, 2016 Category: Neurology Source Type: research
Selective Sphingosine-1-Phosphate Receptor 1 Modulation Attenuates Experimental Intracerebral Hemorrhage Basic Sciences
Conclusions—
S1PR1 modulation via RP101075 provides protection in experimental ICH. Together with the advantageous pharmacological features of RP101075, these results warrant further investigations of its mechanisms of action and translational values in ICH patients.
Source: Stroke - June 26, 2016 Category: Neurology Authors: Sun, N., Shen, Y., Han, W., Shi, K., Wood, K., Fu, Y., Hao, J., Liu, Q., Sheth, K. N., Huang, D., Shi, F.-D. Tags: Intracranial Hemorrhage Basic Sciences Source Type: research
Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation
Publication date: Available online 11 May 2016 Source:The Lancet Neurology Author(s): Ángel Chamorro, Ulrich Dirnagl, Xabier Urra, Anna M Planas Treatments for acute ischaemic stroke continue to evolve after the superior value of endovascular thrombectomy was confirmed over systemic thrombolysis. Unfortunately, numerous neuroprotective drugs have failed to show benefit in the treatment of acute ischaemic stroke, making the search for new treatments imperative. Increased awareness of the relevance of rigorous preclinical testing, and appropriate selection of study participants, might overcome the barriers to progress...
Source: The Lancet Neurology - May 11, 2016 Category: Neurology Source Type: research
Treatment with FTY720 has no beneficial effects on short-term outcome in an experimental model of intracerebral hemorrhage
Conclusions
Our results suggest that FTY720 has no beneficial effects in the acute phase of experimental ICH.
Source: Experimental and Translational Stroke Medicine - February 18, 2016 Category: Neurology Source Type: research
